{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:19:31Z","timestamp":1788185971002,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370185"],"award-info":[{"award-number":["82370185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06336-8","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T23:47:11Z","timestamp":1743896831000},"page":"1459-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone)"],"prefix":"10.1007","volume":"104","author":[{"given":"Xuan","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"9927","key":"6336_CR1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383(9927):1503\u20131516. https:\/\/doi.org\/10.1016\/S0140-6736(13)61048-X","journal-title":"Lancet"},{"issue":"7","key":"6336_CR2","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100(7):2367\u20132373. https:\/\/doi.org\/10.1182\/blood-2002-01-0172","journal-title":"Blood"},{"issue":"13","key":"6336_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"19","key":"6336_CR4","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","volume":"126","author":"Y Wang","year":"2015","unstructured":"Wang Y, Huang W, Hu L et al (2015) Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood 126(19):2186\u20132192. https:\/\/doi.org\/10.1182\/blood-2015-05-644914","journal-title":"Blood"},{"issue":"4","key":"6336_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","volume":"193","author":"J Wang","year":"2021","unstructured":"Wang J, Zhang R, Wu X et al (2021) Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol 193(4):761\u2013768. https:\/\/doi.org\/10.1111\/bjh.17331","journal-title":"Br J Haematol"},{"issue":"12","key":"6336_CR6","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F et al (2019) Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol 6(12):e630\u2013e637. https:\/\/doi.org\/10.1016\/S2352-3026(19)30156-5","journal-title":"Lancet Haematol"},{"issue":"11","key":"6336_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2019003886","volume":"135","author":"P Liu","year":"2020","unstructured":"Liu P, Pan X, Chen C et al (2020) Nivolumab treatment of relapsed\/refractory Epstein-Barr virus\u2013associated hemophagocytic lymphohistiocytosis in adults. Blood 135(11):826\u2013833. https:\/\/doi.org\/10.1182\/blood.2019003886","journal-title":"Blood"},{"key":"6336_CR8","doi-asserted-by":"publisher","unstructured":"Gangat N, Caramazza D, Vaidya R et al (2010) DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Published Online Dec 13. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","DOI":"10.1200\/JCO.2010.32.2446"},{"issue":"24","key":"6336_CR9","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","volume":"139","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhao YZ, Ma HH et al (2022) A study of ruxolitinib response\u2013based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood 139(24):3493\u20133504. https:\/\/doi.org\/10.1182\/blood.2021014860","journal-title":"Blood"},{"issue":"6","key":"6336_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","volume":"8","author":"M Mudireddy","year":"2018","unstructured":"Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A (2018) Validation of the WHO-defined 20% Circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. Blood Cancer J 8(6):57. https:\/\/doi.org\/10.1038\/s41408-018-0095-2","journal-title":"Blood Cancer J"},{"issue":"19","key":"6336_CR11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C et al (2020) Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 382(19):1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1911326","journal-title":"N Engl J Med"},{"issue":"21","key":"6336_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","volume":"134","author":"M Vallurupalli","year":"2019","unstructured":"Vallurupalli M, Berliner N (2019) Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood 134(21):1783\u20131786. https:\/\/doi.org\/10.1182\/blood.2019002289","journal-title":"Blood"},{"issue":"6","key":"6336_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/blood.2020006075","volume":"136","author":"LK Meyer","year":"2020","unstructured":"Meyer LK, Verbist KC, Albeituni S et al (2020) JAK\/STAT pathway Inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood 136(6):657\u2013668. https:\/\/doi.org\/10.1182\/blood.2020006075","journal-title":"Blood"},{"key":"6336_CR14","doi-asserted-by":"publisher","first-page":"1137037","DOI":"10.3389\/fimmu.2023.1137037","volume":"14","author":"S Albeituni","year":"2023","unstructured":"Albeituni S, Oak N, Tillman HS et al (2023) Cellular and transcriptional impacts of Janus kinase and\/or IFN-gamma Inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis. Front Immunol 14:1137037. https:\/\/doi.org\/10.3389\/fimmu.2023.1137037","journal-title":"Front Immunol"},{"issue":"1","key":"6336_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2022.07.026","volume":"151","author":"JA Joly","year":"2023","unstructured":"Joly JA, Vall\u00e9e A, Bourdin B et al (2023) Combined IFN-\u03b3 and JAK Inhibition to treat hemophagocytic lymphohistiocytosis in mice. J Allergy Clin Immunol 151(1):247\u2013259e7. https:\/\/doi.org\/10.1016\/j.jaci.2022.07.026","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"6336_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Emapalumab (2019) First global approval. Drugs 79(1):99\u2013103. https:\/\/doi.org\/10.1007\/s40265-018-1046-8","journal-title":"Drugs"},{"issue":"19","key":"6336_CR17","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","volume":"125","author":"AM Schram","year":"2015","unstructured":"Schram AM, Berliner N (2015) How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125(19):2908\u20132914. https:\/\/doi.org\/10.1182\/blood-2015-01-551622","journal-title":"Blood"},{"issue":"1","key":"6336_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/pbc.22774","volume":"56","author":"TF Lin","year":"2011","unstructured":"Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL (2011) Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer 56(1):154\u2013155. https:\/\/doi.org\/10.1002\/pbc.22774","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"6336_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/gut.42.5.650","volume":"42","author":"E Ebert","year":"1998","unstructured":"Ebert E (1998) Tumour necrosis factor-\u03b1 enhances intraepithelial lymphocyte proliferation and migration. Gut 42(5):650\u2013655","journal-title":"Gut"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06336-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06336-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06336-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:54Z","timestamp":1745575854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06336-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6336"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06336-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Beijing Friendship hospital (Approval No. 2023-P2-321, Date: 2023-11-30).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All human participants involved in this study provided their informed consent prior to participation. The study was conducted in accordance with ethical guidelines, and participants were informed about the purpose, procedures, potential risks, and their right to withdraw at any time without consequences. Written (or verbal, if applicable) consent was obtained from all individuals before their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}